Bayer Reports Results of Nifurtimox in P-III CHICO Study for Chagas Disease in Pediatric Patients

Shots:

• TheP-III CHICO study involves assessing of Nifurtimox (120mg/30mg) vs PBO in 330 pediatric patients with acute or chronic Chagas disease across 25 sites including Argentina, Bolivia, and Colombia
• The P-III CHICO study results: met its 1EPs; superior serological response @60days treatment; safe profile at body weight-adjusted dosing
• Nifurtimox (120mg, 30mg) is a nitro heterocyclic compound available as dispersible tablets used for easy division and improvement in weight adjusted dosing in newborns, infants, and children

Click here to read full press release/ article | Ref: Bayer | Image: Reuters Africa